ArticleInternational journal of chronic obstructive pulmonary disease2014
Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012-2013.
Article in International journal of chronic obstructive pulmonary disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 3 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- Prevalence and Economic Burden of Respiratory Diseases in Central Asia and Russia: A Systematic Review.International journal of environmental research and public health · 2020Pooled it
- Joint statement for the diagnosis, management, and prevention of chronic obstructive pulmonary disease for Gulf Cooperation Council countries and Middle East-North Africa region, 2017.International journal of chronic obstructive pulmonary disease · 2017Guideline
- Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis.International journal of chronic obstructive pulmonary disease · 2017Pooled it
- Polypharmacy Increases Risk of Dyspnea Among Adults With Serious, Life-Limiting Diseases.The American journal of hospice & palliative care · 2020Trial
- Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study.International journal of chronic obstructive pulmonary disease · 2019Trial
- The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.International journal of chronic obstructive pulmonary disease · 2019Trial
- Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease.BMC pulmonary medicine · 2015Trial
- Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD.International journal of chronic obstructive pulmonary diseaseTrial
- Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA.International journal of chronic obstructive pulmonary diseaseTrial
- Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD.International journal of chronic obstructive pulmonary diseaseTrial
- Incidence of acute exacerbation and its related factors among chronic obstructive pulmonary disease patients aged 40 years and older in China.Chinese medical journal pulmonary and critical care medicine · 2026Article
- Spatial epidemiological analysis of chronic obstructive pulmonary disease in Qingdao City, China.Respiratory research · 2026Article
- Global trends and projections of rehabilitation needs in chronic obstructive pulmonary disease, 1990-2050: an analysis using WHO rehabilitation need estimates.Frontiers in public health · 2026Article
- Distance travelled in the six-minute walk test in patients with chronic obstructive pulmonary disease as a predictor of mortality.BMC pulmonary medicine · 2025Article
- BPIFB4 rs4339026 A > G polymorphism impacts COPD susceptibility in the Kashi population, China.Scientific reports · 2025Article
- DECAF Score in Predicting Outcomes of Acute Exacerbation of Chronic Obstructive Pulmonary Disease: An Observational Study.JNMA; journal of the Nepal Medical Association · 2025Observational
- Factors Associated with Initial Treatment Failure in Inpatients with Exacerbation of Chronic Obstructive Pulmonary Disease: A Cohort Study.International journal of chronic obstructive pulmonary disease · 2025Article
- Global, Regional, and National Burden of COPD Among Women from 1990 to 2021 and Projections to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021.Annals of global health · 2025Article
- Article
- Pulmonary hypertension associated with lung diseases.The European respiratory journal · 2024Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe Continuing to Confront COPD International Patient Survey aimed to estimate the prevalence and burden of COPD globally and to update findings from the Confronting COPD International Survey conducted in 1999-2000. MATERIALS AND
methodsChronic obstructive pulmonary disease (COPD) patients in 12 countries worldwide were identified through systematic screening of population samples. Telephone and face-to-face interviews were conducted between November 2012 and May 2013 using a structured survey that incorporated validated patient-reported outcome instruments. Eligible patients were adults aged 40 years and older who were taking regular respiratory medications or suffered with chronic respiratory symptoms and reported either 1) a physician diagnosis of COPD/emphysema, 2) a physician diagnosis of chronic bronchitis, or 3) a symptom-based definition of chronic bronchitis. The burden of COPD was measured with the COPD Assessment Test (CAT) and the modified Medical Research Council (mMRC) Dyspnea Scale.
resultsOf 106,876 households with at least one person aged ≥40 years, 4,343 respondents fulfilled the case definition of COPD and completed the full survey. COPD prevalence ranged from 7% to 12%, with most countries falling within the range of 7%-9%. In all countries, prevalence increased with age, and in all countries except the US was greater among men (range 6%-14%) than among women (range 5%-11%). A significant disease burden was observed when considering COPD symptoms or health status, and showed wide variations across countries. Prevalence of moderate-to-severe dyspnea (mMRC scale ≥2) ranged from 27% to 61%, and mean CAT score ranged from 16.0 to 24.8, indicating medium-to-high impairment.
conclusionThis survey, representing 12 countries, showed similar rates of estimated COPD prevalence across countries that were higher than those reported a decade ago in the original Confronting COPD International Survey. A significant burden of COPD was demonstrated by symptoms and health care-resource use, similar to that reported in the original survey.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.